These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33335905)

  • 1. Determination of a "Specific Population Who Could Benefit From Rosuvastatin": A Secondary Analysis of a Randomized Controlled Trial to Uncover the Novel Value of Rosuvastatin for the Precise Treatment of ARDS.
    Zhang S; Lu Z; Wu Z; Xie J; Yang Y; Qiu H
    Front Med (Lausanne); 2020; 7():598621. PubMed ID: 33335905
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of total cholesterol and statin therapy on mortality in ARDS patients: a secondary analysis of the SAILS and HARP-2 trials.
    Pienkos SM; Moore AR; Guan J; Levitt JE; Matthay MA; Baron RM; Conlon J; McAuley DF; O'Kane CM; Rogers AJ
    Crit Care; 2023 Mar; 27(1):126. PubMed ID: 36978134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Rosuvastatin on Acute Kidney Injury in Sepsis-Associated Acute Respiratory Distress Syndrome.
    Hsu RK; Truwit JD; Matthay MA; Levitt JE; Thompson BT; Liu KD
    Can J Kidney Health Dis; 2018; 5():2054358118789158. PubMed ID: 30116543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine Learning Classifier Models Can Identify Acute Respiratory Distress Syndrome Phenotypes Using Readily Available Clinical Data.
    Sinha P; Churpek MM; Calfee CS
    Am J Respir Crit Care Med; 2020 Oct; 202(7):996-1004. PubMed ID: 32551817
    [No Abstract]   [Full Text] [Related]  

  • 6. One-year outcomes of rosuvastatin versus placebo in sepsis-associated acute respiratory distress syndrome: prospective follow-up of SAILS randomised trial.
    Dinglas VD; Hopkins RO; Wozniak AW; Hough CL; Morris PE; Jackson JC; Mendez-Tellez PA; Bienvenu OJ; Ely EW; Colantuoni E; Needham DM
    Thorax; 2016 May; 71(5):401-10. PubMed ID: 26936876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin for sepsis-associated acute respiratory distress syndrome.
    ; Truwit JD; Bernard GR; Steingrub J; Matthay MA; Liu KD; Albertson TE; Brower RG; Shanholtz C; Rock P; Douglas IS; deBoisblanc BP; Hough CL; Hite RD; Thompson BT
    N Engl J Med; 2014 Jun; 370(23):2191-200. PubMed ID: 24835849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study.
    Sinha P; Delucchi KL; Thompson BT; McAuley DF; Matthay MA; Calfee CS;
    Intensive Care Med; 2018 Nov; 44(11):1859-1869. PubMed ID: 30291376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Best evidence in critical care medicine: The role of neuromuscular blocking drugs in early severe acute respiratory distress syndrome.
    Needham CJ; Brindley PG
    Can J Anaesth; 2012 Jan; 59(1):105-8. PubMed ID: 22042702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of distinct clinical phenotypes of acute respiratory distress syndrome with differential responses to treatment.
    Liu X; Jiang Y; Jia X; Ma X; Han C; Guo N; Peng Y; Liu H; Ju Y; Luo X; Li X; Bu Y; Zhang J; Liu Y; Gao Y; Zhao M; Wang H; Luo L; Yu K; Wang C
    Crit Care; 2021 Aug; 25(1):320. PubMed ID: 34461969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials.
    Sinha P; Delucchi KL; McAuley DF; O'Kane CM; Matthay MA; Calfee CS
    Lancet Respir Med; 2020 Mar; 8(3):247-257. PubMed ID: 31948926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of procalcitonin on predicting the severity and prognosis in patients with early ARDS: a prospective observation study].
    Yu Z; Ji M; Hu X; Yan J; Jin Z
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 Jan; 29(1):34-38. PubMed ID: 28459401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARDS Patients Exhibiting a "Hyperinflammatory Anasarca" Phenotype Could Benefit From a Conservative Fluid Management Strategy.
    Xing CY; Gong WB; Yang YN; Qi XJ; Zhang S
    Front Med (Lausanne); 2021; 8():727910. PubMed ID: 34513888
    [No Abstract]   [Full Text] [Related]  

  • 14. Rosuvastatin versus placebo for delirium in intensive care and subsequent cognitive impairment in patients with sepsis-associated acute respiratory distress syndrome: an ancillary study to a randomised controlled trial.
    Needham DM; Colantuoni E; Dinglas VD; Hough CL; Wozniak AW; Jackson JC; Morris PE; Mendez-Tellez PA; Ely EW; Hopkins RO
    Lancet Respir Med; 2016 Mar; 4(3):203-12. PubMed ID: 26832963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using machine learning for the early prediction of sepsis-associated ARDS in the ICU and identification of clinical phenotypes with differential responses to treatment.
    Bai Y; Xia J; Huang X; Chen S; Zhan Q
    Front Physiol; 2022; 13():1050849. PubMed ID: 36579020
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
    McMurray JJ; Kjekshus J; Gullestad L; Dunselman P; Hjalmarson A; Wedel H; Lindberg M; Waagstein F; Grande P; Hradec J; Kamenský G; Korewicki J; Kuusi T; Mach F; Ranjith N; Wikstrand J;
    Circulation; 2009 Dec; 120(22):2188-96. PubMed ID: 19917888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
    Dixon B; Smith RJ; Campbell DJ; Moran JL; Doig GS; Rechnitzer T; MacIsaac CM; Simpson N; van Haren FMP; Ghosh AN; Gupta S; Broadfield EJC; Crozier TME; French C; Santamaria JD;
    Lancet Respir Med; 2021 Apr; 9(4):360-372. PubMed ID: 33493448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome.
    Gates S; Perkins GD; Lamb SE; Kelly C; Thickett DR; Young JD; McAuley DF; Snaith C; McCabe C; Hulme CT; Gao Smith F
    Health Technol Assess; 2013 Sep; 17(38):v-vi, 1-87. PubMed ID: 24028755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis.
    Seymour CW; Kennedy JN; Wang S; Chang CH; Elliott CF; Xu Z; Berry S; Clermont G; Cooper G; Gomez H; Huang DT; Kellum JA; Mi Q; Opal SM; Talisa V; van der Poll T; Visweswaran S; Vodovotz Y; Weiss JC; Yealy DM; Yende S; Angus DC
    JAMA; 2019 May; 321(20):2003-2017. PubMed ID: 31104070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.